SCHEMBL25140232

SCHEMBL25140232

Cc1cc(OCc2ccc(O)c(C(F)(F)F)c2)cc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.40
MAOB P27338 8/20 0.39
MRGPRX4 Q96LA9 3/20 0.39
AR P10275 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
RXRG P48443 1/20 0.38
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21958646 0.77 GRM5 (0.51) MAOBMRGPRX4ARNR4A2
SCHEMBL21945019 0.75 IDO1 (0.55) MAOBMRGPRX4
SCHEMBL14924831 0.73 FFAR1 (0.41) L3MBTL1MAOBARFFAR1
SCHEMBL14421293 0.71 CA1 (0.54) MAPTPOLB
SCHEMBL29485598 0.71 CA1 (0.54) MAPTPOLB
SCHEMBL16729641 0.70 MAPT (0.50) MAPTHTTL3MBTL1RXRARXRB
SCHEMBL13180038 0.70 RXRA (0.48) MAPTL3MBTL1POLBMAOBRXRA
SCHEMBL21944990 0.70 MAOB (0.49) MAPTPOLBMAOBMRGPRX4FFAR1
SCHEMBL14421294 0.69 CA1 (0.52) MAPTPOLB
SCHEMBL13699127 0.69 TP53 (0.44) L3MBTL1RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230121233-A1 Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same ACCRO BIOSCIENCE (HK) LIMITED (HK) 2023-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230121233-A1 Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same BAX, PDCD1, PDCD4 MAPT 1983/4885HTT 2103/4885L3MBTL1 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.